FDA Reviews Shin Nippon Biomedical Laboratories' Resubmitted NDA for Migraine Treatment STS101
FDA Reviews Shin Nippon Biomedical Laboratories' Resubmitted NDA for Migraine Treatment STS101
FDA審核了新日本生物醫藥實驗室重新提交的用於治療偏頭痛的NDA申請STS101
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間